TRANSPARENCY COMMITTEE SUMMARY 16 JUNE 2020

The legally binding text is the original French opinion version

aclidinium bromide
EKLIRA GENUAIR (aclidinium bromide) 322 µg inhalation powder

Reevaluation

► Key points

Favourable opinion for reimbursement as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). The clinical benefit is now substantial, where previously it was insufficient.

► What therapeutic improvement?

No clinical added value relative to tiotropium.

► Role in the care pathway?

The diagnosis and management of patients with COPD must include an assessment of the COPD severity stage based on symptoms (chronic cough, dyspnoea on exertion, purulent expectoration, exacerbations) and lung function status.

Quitting smoking is the only measure liable to slow the decline in FEV₁. Influenza vaccination is recommended. To date, no medicinal products have demonstrated an effect on prevention of progression of COPD towards chronic respiratory insufficiency. Cardiorespiratory rehabilitation for exercise leads to an improvement in symptoms, quality of life and participation in activities of daily

living, and helps reduce the incidence of exacerbations. The choice of medicinal treatments depends on the symptoms (dyspnoea, exacerbations).

The medicinal management of COPD, outside of exacerbations, is conducted in steps, depending on the severity stage and the response to treatment. The medicinal products used are aimed at:

- Preventing and controlling symptoms;
- Reducing the frequency and severity of exacerbations;
- Improving quality of life;
- Improving exercise tolerance.

Long-acting β 2-adrenergic agonist (LABA) and long-acting muscarinic antagonist (LAMA) bronchodilators are recommended when maintenance symptomatic treatment is required, i.e., when daily dyspnoea or exacerbations persist despite the repeated daily use of a short-acting bronchodilator.

A clinical and functional reassessment is offered after 1 to 3 months then every 3 to 12 months, depending on the severity of the COPD.

If dyspnoea persists, the combination of a long-acting β 2-adrenergic agonist (LABA) and a long-acting muscarinic antagonist (LAMA) may improve lung function (FEV_1), quality of life and dyspnoea and reduce exacerbations without increasing adverse effects.

In the event of frequent exacerbations despite optimal bronchodilator treatment, a combination of LABA + inhaled corticosteroids (ICS) may be proposed, complying with the FEV_1 levels of the MA, or, in the event of associated dyspnoea ($mMRC \geq 2$), a LABA + LAMA combination. Triple therapy (LABA + LAMA + ICS) is indicated if exacerbations persist despite one of these options. If dyspnoea or exacerbations persist despite triple therapy, other treatments should be envisaged (macrolides if exacerbations, low-dose morphine derivatives if refractory dyspnoea, discussion of endobronchial treatments in a specialised centre).

Continuous oxygen therapy is reserved for patients with daytime hypoxaemia ($PaO_2 \leq 55$ mmHg) observed outside an acute episode despite optimal treatment.

Role of the medicinal product in the care pathway

EKLIRA GENUAIR (aclidinium bromide), a long-acting muscarinic antagonist bronchodilator (LAMA), is a maintenance symptomatic treatment for COPD when symptoms persist despite the use of a short-acting bronchodilator several times daily. It should only be continued if the patient perceives a benefit.

COMMITTEE'S CONCLUSIONS

Clinical benefit

- ▶ COPD leads to disability and a marked deterioration in quality of life and may be life-threatening.
- ▶ This proprietary medicinal product is a maintenance symptomatic treatment for COPD. It has no impact on the long-term decline of lung function.
- ▶ The efficacy/adverse effects ratio is modest.
- ▶ There are medicinal alternatives.
- ▶ This proprietary medicinal product is a first-line treatment.

- ▶ Public health impact:

Considering:

- the seriousness of COPD,
- its prevalence,
- the partially met medical need,
- the absence of robust data on quality of life,
- the lack of any demonstrated impact on the organisation of care,
- the partial response to the identified need with no demonstrated impact on quality of life,
- EKLIRA GENUAIR (aclidinium bromide) is unlikely to have an additional impact on public health.

Given all these elements, the Committee deems that the clinical benefit of EKLIRA GENUAIR (aclidinium bromide) is substantial in the MA indication.

The Committee issues a favourable opinion for inclusion in both the hospital formulary list and the retail formulary list of reimbursed proprietary medicinal products approved for use in the marketing authorisation indication(s) and dosages.

Clinical Added Value

Considering:

- demonstration of the non-inferiority of aclidinium compared to tiotropium in terms of pre-dose FEV₁, an intermediate endpoint (0.007 L (95% CI [-0.021; 0.035]));
- demonstration of an efficacy of aclidinium on the annual rate of moderate to severe exacerbations, but only compared to placebo (0.44 in the aclidinium group and 0.57 in the placebo group, RR=0.78; 95% CI [0.68; 0.89]);
- the absence of comparative data on the impact on quality of life;
- the medical need partially met by the existence of alternatives having demonstrated a modest efficacy on bronchodilation;

the Transparency Committee considers that EKLIRA GENUAIR (aclidinium bromide) provides no clinical added value (CAV V) compared to tiotropium in the maintenance treatment of COPD symptoms.